Leap Therapeutics Files 8-K for 'Other Events' on Jan 23, 2024

Ticker: CYPH · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1509745

Leap Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form Type8-K
Filed DateJan 23, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-event, regulatory-filing

TL;DR

**Leap Therapeutics filed an 8-K, signaling a potentially significant upcoming announcement.**

AI Summary

Leap Therapeutics, Inc. filed an 8-K on January 23, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the company is communicating information to the SEC, potentially related to a significant corporate action or disclosure. For investors, this matters because 8-K filings often precede or announce material events that can impact the stock price, such as mergers, acquisitions, or new drug developments, making it crucial to monitor for further details.

Why It Matters

This 8-K signals that Leap Therapeutics, Inc. has a new material event to disclose, which could influence investor sentiment and stock valuation. Investors should look for subsequent filings or press releases to understand the specific nature of this 'Other Event'.

Risk Assessment

Risk Level: medium — The 'Other Events' category in an 8-K can cover a wide range of disclosures, some of which could be highly impactful, creating uncertainty until more details are released.

Analyst Insight

A smart investor would add LPTX to their watchlist and set up alerts for any subsequent filings or news releases from Leap Therapeutics, Inc. to understand the specific nature of the 'Other Event' and its potential impact on the stock.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Leap Therapeutics, Inc.?

The primary purpose of this 8-K filing, dated January 23, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits' as per Item Information.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 23, 2024.

What is the trading symbol and the exchange where Leap Therapeutics, Inc.'s Common Stock is registered?

Leap Therapeutics, Inc.'s Common Stock trades under the symbol LPTX and is registered on the Nasdaq Capital Market.

What is the state of incorporation for Leap Therapeutics, Inc.?

Leap Therapeutics, Inc. is incorporated in Delaware.

What is the par value of Leap Therapeutics, Inc.'s Common Stock?

The par value of Leap Therapeutics, Inc.'s Common Stock is $0.001.

Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-01-23 17:28:43

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events On January 23, 2024, Leap Therapeutics, Inc. (the "Company") posted an updated corporate presentation on its website, www.leaptx.com. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained on, or that can be accessed from, the Company's website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Leap Corporate Presentation 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: January 23, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing